| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.0 | 0.0 |
| Profit before tax | -108.6 | -90.2 |
| Net income | -110.4 | -90.9 |
| EPS (diluted, $ a share) | $-1.11 | $-1.15 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: XENE. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Xenon Pharmaceuticals Inc.: key numbers
- Share price
- $39.26Close, Nov 16
- Market cap
- $3.86B
- Shares outstanding
- 98.28MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Xenon Pharmaceuticals Inc.
All →Xenon Pharmaceuticals Financial Results
Xenon Pharmaceuticals reported Q3 2026 financial results, highlighting the submission of its New Drug Application (NDA) for azetukalner in focal seizures to the FDA in September 2026. The company ended the quarter with $1.2 billion in cash and marketable securities, providing a projected cash runway into 2029 as it prepares for topline Phase 3 MDD data in December 2026.
- Term
- Q3 2026
“We've made significant progress advancing azetukalner with our recent NDA submission to the FDA for focal seizures and through ongoing scientific exchange opportunities. We continue to have great confidence in azetukalner’s product profile in epilepsy based on strong efficacy and consistent safety across more than 1,500 patient-years of data, which has been reiterated in conversations with both epileptologists and neurologists.”
Ian Mortimer, President and Chief Executive Officer
Xenon Pharmaceuticals CFO Thomas Patrick Kelly Buys $560K of Stock
Thomas Patrick Kelly, CFO, bought 15,000 shares of Xenon Pharmaceuticals Inc. at $37.32 a share, worth $560K in total on Sep 30, 2026. Shares held after the trade: 15,000.
- Value
- $560K
- Shares
- 15,000
- Price
- $37.32
- Role
- CFO
- Trade date
- Sep 30, 2026
Xenon Pharmaceuticals President & CEO Ian Mortimer Buys $1.12M of Stock
Ian Mortimer, President & CEO, bought 30,000 shares of Xenon Pharmaceuticals Inc. at $37.38 a share, worth $1.12M in total on Sep 30, 2026. Shares held after the trade: 49,923 (+150.6%).
- Value
- $1.12M
- Shares
- 30,000
- Price
- $37.38
- Role
- President & CEO
- Holding change
- +150.6%
- Trade date
- Sep 30, 2026